

## AMENDMENT

### In the Claims:

1. (Amended) An isolated antimicrobial peptide of not more than 50 residues, the peptide comprising an amino acid sequence selected from the group consisting of:

KNLRRIRKIIHIKKYG-NH<sub>2</sub> (SEQ ID NO: 1),  
KNIRRIIRKIIHIKKYG-NH<sub>2</sub> (SEQ ID NO: 6),  
KNIRRIIRKIIHIKKYG (SEQ ID NO: 7),  
KNLRRIRKIIHIKKY<sup>˙</sup>G (SEQ ID NO: 8),  
NLRRIRKIIHIKKY (SEQ ID NO 9),  
NIRRIIRKIIHIKKY (SEQ ID NO: 10),  
LRRIRKIIHIKK-NH<sub>2</sub> (SEQ ID NO: 11),  
LRRIRKIIHIKK (SEQ ID NO: 12),  
IRRIIRKIIHIKK-NH<sub>2</sub> (SEQ ID NO: 13),  
IRRIIRKIIHIKK (SEQ ID NO: 14),  
LRRIRKIIHIK-NH<sub>2</sub> (SEQ ID NO: 15),  
RRIIRKIIHIKK-NH<sub>2</sub> (SEQ ID NO: 16),  
RRIIRKIIHIK-NH<sub>2</sub> (SEQ ID NO: 17),  
GLRKRLRKFRNKIKEKLKKIG (SEQ ID NO: 19),  
KRLRKFRNKIKEKLKKIG (SEQ ID NO: 20),  
RKRLRKFRNKIKEKLKKIGQKI (SEQ ID NO: 21),  
LRKFRNKIKEKLKKIGQKI (SEQ ID NO: 22),  
LRKFRNKIKEKLKKIGQKI<sup>˙</sup>Q (SEQ ID NO: 23),  
RKFRNKIKEKLKKIG (SEQ ID NO: 24),  
KIKEKLKKIGQKI<sup>˙</sup>Q (SEQ ID NO: 25),  
KIKEKLKKIGQKI<sup>˙</sup>QGLL (SEQ ID NO: 26),  
RGLRRLGRKIAHGVKKYGPTVLRRIIRIA-NH<sub>2</sub> (SEQ ID NO. 27), and  
KNLRRIRKIIHIKKYGPTILRIIRIIG-NH<sub>2</sub> (SEQ ID NO. 28).

3. (Amended) A pharmaceutical composition comprising an antimicrobial peptide of not more than 50 residues, the peptide comprising an amino acid sequence selected from the group consisting of:

KNLRRRIIRKIIHIIKKYG-NH<sub>2</sub> (SEQ ID NO: 1),  
KNIRRIIRKIIHIIKKYG-NH<sub>2</sub> (SEQ ID NO: 6),  
KNIRRIIRKIIHIIKKYG (SEQ ID NO: 7),  
KNLRRRIIRKIIHIIKKYG (SEQ ID NO: 8),  
NLRRRIIRKIIHIIKKY (SEQ ID NO 9),  
NIRRIIRKIIHIIKKY (SEQ ID NO: 10),  
LRRRIIRKIIHIIKK-NH<sub>2</sub> (SEQ ID NO: 11),  
LRRRIIRKIIHIIKK (SEQ ID NO: 12),  
IRRIIRKIIHIIKK-NH<sub>2</sub> (SEQ ID NO: 13),  
IRRIIRKIIHIIKK (SEQ ID NO: 14),  
LRRRIIRKIIHIIK-NH<sub>2</sub> (SEQ ID NO: 15),  
RRIIRKIIHIIKK-NH<sub>2</sub> (SEQ ID NO: 16),  
RRIIRKIIHIIK-NH<sub>2</sub> (SEQ ID NO: 17),  
GLRKRLRKFRNKIKEKLKKIG (SEQ ID NO: 19),  
KRLRKFRNKIKEKLKKIG (SEQ ID NO: 20),  
RKRLRKFRNKIKEKLKKIGQKI (SEQ ID NO: 21),  
LRKFRNKIKEKLKKIGQKI (SEQ ID NO: 22),  
LRKFRNKIKEKLKKIGQKIQG (SEQ ID NO: 23),  
RKFRNKIKEKLKKIG (SEQ ID NO: 24),  
KIKEKLKKIGQKIQG (SEQ ID NO: 25),  
KIKEKLKKIGQKIQGLL (SEQ ID NO: 26),  
RGLRRLGRKIAHGVKKYGPTVLRRIIRIA-NH<sub>2</sub> (SEQ ID NO. 27), and  
KNLRRRIIRKIIHIIKKYGPTILRIIRIIG-NH<sub>2</sub> (SEQ ID NO. 28),  
formulated in a pharmaceutically acceptable carrier.